HBHelen D. Berlie

Helen D. Berlie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Helen D. Berlie has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Blueprint for Developing a Concentration in Ambulatory Care Within the PharmD Curriculum

    by Helen Berlie, Amber Lanae Martirosov, Brittany Stewart, Candice Garwood

    The US healthcare system is grappling with significant challenges, notably a shortage of primary care providers. Ambulatory care pharmacists are increasingly recognized as vital contributors to addressing these challenges. The Accreditation Council for Pharmacy Education Standards 2025 emphasizes preparing Doctor of Pharmacy (PharmD) graduates to be both “practice‐ready” and “team‐ready,” supporting pharmacists' expanding role in addressing primary care shortages as members of interprofessional ambulatory care teams. The evolving healthcare landscape, local community needs, and directives from national pharmacy organizations underscore the importance of developing ambulatory care‐focused curricular concentrations within PharmD programs. In this paper, we describe the development, implementation, and initial evaluation of an ambulatory care concentration (ACC) within a PharmD curriculum and provide a framework adaptable for other pharmacy programs seeking specialized curricular pathways. The purpose of the ACC was to prepare graduates for entry‐level ambulatory care practice and postgraduate training. Graduates of the inaugural ACC cohort reported high overall satisfaction with the concentration and enhanced preparedness for ambulatory care practice. Early career outcomes include three graduates currently completing ambulatory care residencies. The seven graduates in practice are in ambulatory care, specialty pharmacy, managed care, clinical community pharmacy, community pharmacy ( n = 2), and inpatient clinical practice (post‐residency). The ACC was implemented within the PharmD curriculum and was well received by students. Early findings support the purpose of the ACC to prepare graduates for ambulatory care practice and postgraduate training. This model provides an approach that pharmacy programs may adapt to develop practice‐focused curricular pathways by leveraging existing institutional resources.

  • Aspirin Deprescribing Interventions for Primary Prevention: A Systematic Review and Proposed Guidance for Deprescribing

    by Alison Lobkovich, Hannah Ferrari, Amber Lanae Martirosov, Insaf Mohammad, Helen Berlie, Candice Garwood, Melissa Lipari

    Recent literature indicates that the benefits of aspirin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD) may be equivocal to the risk. This has resulted in several organizations making updates to their clinical practice guidance on appropriate use. Despite this narrower scope, specific guidance on how to deprescribe aspirin in patients already on therapy for primary prevention is lacking. The purpose of this paper is two‐fold: to provide a systematic review of the literature on aspirin deprescribing strategies and propose a practical aspirin deprescribing algorithm when used discordantly with current recommendations for primary prevention. We conducted searches in databases including EMBASE, PubMed, Web of Science, Scopus, and CINAHL from January 2018 to March 2025. One hundred and sixty‐seven studies were screened, and 13 articles were included. The studies utilized a variety of interventions to impact aspirin deprescribing. In each of the studies included, there was at least some type of prompt to trigger deprescribing aspirin. However, a consistent approach was not defined. A multidisciplinary model occurred in half of the studies included, which resulted in the highest reported deprescribing rate of 78%. However, there were limited descriptions of patient‐related outcomes as a result of deprescribing, warranting additional studies. A deprescribing algorithm can assist in guiding aspirin deprescribing for primary prevention of ASCVD while considering patient preferences in an individually tailored approach.


  • Clinician Perceptions of Therapeutic Inertia in Type 2 Diabetes Mellitus: A Qualitative Study

    by Melissa Lipari, Candice L. Garwood, Helen Berlie, Charles E. Leonard

    Background: Therapeutic inertia (TI) in type 2 diabetes mellitus (T2DM) is defined as the lack of timely adjustment to therapy when a patient's treatment goals are not met. Failure to initiate or intensify evidence‐based therapies for T2DM increases the risk of micro and macrovascular disease complications. There are limited data regarding clinicians' (nurse practitioners and pharmacists) perceptions of TI and patient‐perceived barriers to therapeutic progress in T2DM. A better understanding of perceptions of TI might assist in identifying targeted interventions to limit its occurrence. The objective of this study was to determine perceived factors that contribute to TI in patients with T2DM from a primary care clinician perspective. Methods: This was a multi‐centered prospective qualitative study. Purposive sampling was used. Primary care clinicians, licensed in the state of Michigan and treating patients with T2DM, were assessed on their attitudes and beliefs toward TI in the treatment of T2DM. Participant interviews were conducted by one investigator, and responses were independently reviewed by two separate investigators. Data were coded, organized, and analyzed using Dedoose software. Results: Fourteen participants completed the study. Clinicians in the study were predominately pharmacists (57.1%) and female (92.9%) and the majority had more than 10 years of practice experience (57.1%). Major themes identified to help overcome TI were the importance of patient education, empathy toward the patient, and team collaboration. Therapeutic barriers identified by clinicians included cost, clinician/clinic time, and patient accountability. Several perceived facilitators and barriers to TI in the management of T2DM were identified. Clinicians described a team‐based approach with clearly delineated and complementary roles between clinicians to support patient care and minimize TI. Conclusions: TI remains a persistent problem in clinical practice. Several opportunities exist to reduce TI in patients with T2DM, which include a multidisciplinary approach to care and improved access to medications and services (transportation, nutrition education, etc.).

  • Continuous Glucose Monitoring User-Wear Experience Fosters Empathy and Learning

    by Alison Lobkovich, Rena Dabish, Alexandra Maria Gavrilidis, Brian Globerman, Helen D. Berlie


  • Integrating continuous glucose monitoring into Doctor of Pharmacy curricula

    by Kathryn Litten, Heather Folz, Alison Lobkovich, Christina H. Sherrill, Helen Berlie

    The use of digital health technology is on the rise. Within diabetes care, continuous glucose monitoring (CGM) is transforming how we monitor and manage patients with diabetes. Pharmacists play pivotal roles in CGM education, accessibility, utility, and application. In turn, pharmacy students should have a working knowledge of these devices. Currently, CGM inclusion in Doctor of Pharmacy (Pharm.D.) curricula is variable, and little is known about the best way to incorporate this content. This article highlights the critical need to intentionally integrate CGM into didactic and experiential teaching. Incorporating CGM education should be individualized to the institution and the level of the trainee. Educational approaches such as patient cases and hands‐on activities can enhance CGM‐related knowledge, skills, confidence, and empathy, which may empower trainees to be practice‐ready and provide essential CGM services after graduation. This guide will provide a suggested framework for integrating CGM into Pharm.D. curricula.


  • The struggle is real: Facilitating pharmacy student success on rotations when challenges arise

    by Insaf Mohammad, Alison Lobkovich, Amber Lanae Martirosov, Melissa Lipari, Candice L. Garwood, Francine D. Salinitri, Justine S. Gortney, Helen D. Berlie


  • Accidental Once-Daily Use of Dulaglutide: A Case Report

    by Hannah E. Moore, Viva Zaya, Carly V. Burns, Helen D. Berlie


  • Evaluation of an ambulatory care elective to improve practice readiness perceptions utilizing entry-level competencies

    by Joseph A. Nardolillo, Alison Lobkovich, Helen Berlie, Jewel Konja, Francine Salinitri, Amber Lanae Martirosov


  • Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review

    by Helen D. Berlie, Pramodini B. Kale-Pradhan, Tara Orzechowski, Linda A. Jaber

    To explore mechanistic benefits of glucose-lowering agents that extend beyond glycemic control with the potential to mitigate coronavirus disease 2019 (COVID-19) complications. The following PubMed literature search terms were used from July 2020 to January 2, 2021: diabetes, COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), glucose-lowering agents, and pharmacology. English-language studies reporting on the association between diabetes, COVID-19 adverse outcomes, and the potential roles of glucose-lowering agents were reviewed. Selected glucose-lowering agents have benefits beyond glycemic control, with the potential to reduce the risks of severe complications during SARS-CoV-2 infection. Key benefits include anti-inflammatory, anticoagulant, immune modulating, and enzyme/receptor effects. This review summarizes the current knowledge of glucose-lowering agents and their potential roles in COVID-19 outcomes. Considering beneficial mechanisms on COVID-19 outcomes that extend beyond glycemic control as well as safety profiles, current data suggest that dipeptidyl peptidase-IV (DPP-IV) inhibitors and metformin may have the most promise and warrant further investigation. Certain glucose-lowering agents may offer additional benefits beyond glucose control—namely, by modulating the mechanisms contributing to adverse outcomes related to COVID-19 in patients with diabetes. DPP-IV inhibitors and metformin appear to have the most promise. However, current published literature on diabetes medications and COVID-19 should be interpreted with caution. Most published studies are retrospective and consist of convenience samples, and some lack adequate analytical approaches with confounding biases. Ongoing trials aim to evaluate the effects of glucose-lowering agents in reducing the severity of COVID-19 outcomes.


  • Open Access

    Ambulatory care practice in the COVID‐19 era: Redesigning clinical services and experiential learning

    by Insaf Mohammad, Helen D. Berlie, Melissa Lipari, Amber Lanae Martirosov, Andrea A. Duong, Maggie Faraj, Opal Bacon, Candice L. Garwood

    The coronavirus disease (COVID‐19) has created a variety of challenges for health care professionals, including ambulatory care clinical pharmacists. High‐quality remote and minimal‐contact care has become a necessity. Ambulatory care clinical pharmacists around the nation have adjusted their practice. In many cases, this included implementation of telehealth programs for comprehensive medication management. The redesign of ambulatory care Advanced Pharmacy Practice Experiences (APPE) also required quick adaptation. In this paper, we describe the clinical practice and experiential education challenges encountered by an ambulatory care clinical pharmacist workgroup in a COVID‐19 “hotspot,” with an emphasis on solutions and guidance. We discuss how to adapt ambulatory care clinical pharmacy practices including methods of minimal‐contact care, reimbursement opportunities, tracking outcomes, and restructuring ambulatory care APPE. As ambulatory care clinical pharmacists continue to expand the services they provide in response to COVID‐19, we also describe opportunities to promote pharmacists as providers during times of pandemic and into the future.